Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Dexmedetomidine for Acute Management of Intrathecal Baclofen Withdrawal
Adam L. Gottula
, Kari L. Gorder
, Amanda R. Peck
, B. Christian Renne
Research output
:
Contribution to journal
›
Article
›
peer-review
7
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dexmedetomidine for Acute Management of Intrathecal Baclofen Withdrawal'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Baclofen Withdrawal
100%
Dexmedetomidine
100%
Intrathecal Baclofen
100%
Acute Management
100%
Emergency Medicine
28%
Pediatric Patients
14%
Oral Baclofen
14%
Hypertension
14%
High Dose
14%
Nursing Facility
14%
Safety Profile
14%
Benzodiazepines
14%
Multiple Organ Failure
14%
Intubated
14%
Spasticity
14%
Intubation
14%
Tachycardia
14%
Severe Cases
14%
Hospital Days
14%
Airway Protection
14%
Dantrolene
14%
Propofol Dose
14%
Acute Setting
14%
Cyproheptadine
14%
Baclofen Pump
14%
Dexmedetomidine Infusion
14%
Withdrawal Syndrome
14%
New Neurologic Deficit
14%
Pharmacology, Toxicology and Pharmaceutical Science
Intrathecal
100%
Dexmedetomidine
100%
Baclofen
100%
Toxic Injury
9%
Withdrawal Syndrome
9%
Multiple Organ Failure
9%
Propofol
9%
Intubation
9%
Tachycardia
9%
Dantrolene
9%
Spasticity
9%
Cyproheptadine
9%
Nursing and Health Professions
Dexmedetomidine
100%
Baclofen
100%
Emergency Physician
20%
Multiple Organ Failure
10%
Outpatient Department
10%
Benzodiazepine Derivative
10%
Pediatrics Patient
10%
Tachycardia
10%
Intrathecal Baclofen Pump
10%
Intubation
10%
Infusion
10%
Withdrawal Syndrome
10%
Propofol
10%
Dantrolene
10%
Spasticity
10%
Cyproheptadine
10%
Medicine and Dentistry
Baclofen
100%
Dexmedetomidine
100%
Pediatrics Patient
9%
Withdrawal Syndrome
9%
Intubation
9%
Multiple Organ Dysfunction Syndrome
9%
Infusion
9%
Propofol
9%
Tachyarrhythmia
9%
Dantrolene
9%
Cyproheptadine
9%
Spasticity
9%
Benzodiazepine Derivative
9%
Oral
9%
Established Treatment
9%